4 6 the increased number of positive results at all hospitals (24). This might be appropriate if all 116 toxin-negative patients with C. difficile detected by NAAT had CDI clinically, but this is not 117 the case (2, 3, 8) . Recent outcome studies show that most toxin-negative patients with C. 118 difficile detected by NAAT or culture recover spontaneously without treatment and have a 119 significantly lower rate of adverse events than toxin-positive patients; furthermore, the 120 duration of symptoms for toxin-negative patients with C. difficile detected by NAAT is 121 similar to that for C. difficile-negative control patients (1, 2, 25) . These findings suggest that 122 using NAAT as a standalone test for CDI diagnosis results in a considerable amount of over-123 diagnosis that has important clinical, financial, and reputational implications for hospitals (2, 124 25). For this reason, guidelines in the UK and Europe now recommend toxin testing to 125 confirm CDI in NAAT-positive patients, and consideration of other causes for symptoms 126 before diagnosis and treatment of CDI in toxin-negative patients (3). 127 7 because 027 strains tend to attain higher organism burdens. The calculated sensitivity of the 138 GDH immunoassay is dependent on the sensitivity of the comparator method, and studies 139 including a blinded multi-center trial using the most sensitive comparators (NAAT and 140 toxigenic culture with detection of both spores and vegetative cells) have shown that GDH 141
assays miss approximately 20% of specimens detected by NAAT in patients with 142 symptomatic CDI (17, 27, 28). In short, a GDH-based algorithm is less costly but sacrifices 143
sensitivity. 144
Polage and Wilcox-GDH detection is sensitive for CDI because C. difficile vegetative cells 145 express and secrete GDH extracellularly, and GDH may play a role in C. difficile 146 colonization in vivo (29) . As a result, most clinical samples with toxigenic C. difficile 147 detectable by culture or NAAT are positive by GDH immunoassays and virtually all samples 148 with toxins detectable are positive for GDH (3, 9, 30). The occasional samples that are 149 positive by NAAT but negative for GDH have a low concentration of C. difficile and no 150 toxins, suggesting that these are most likely C. difficile carriers or patients on treatment (30). 151
Most laboratory comparisons find that GDH immunoassays are >90% sensitive for C. 152 difficile, as confirmed by two meta-analyses; a few studies report slightly lower sensitivities 153 in the range of 83.1-87.6% (3, 9, 26). In the most recent meta-analysis, the pooled sensitivity 154 of GDH immunoassays was 94% (95% CI, 89-97%) and 96% (95% CI, 86-99%) relative to 155 cell cytotoxin neutralization assay and toxigenic culture, respectively; the pooled specificity 156 was 90-96% (3). Finally, recent studies showed that GDH expression is a reliable cost-effectiveness analysis has determined that NAAT is the most cost-effective approach 169 from an institutional standpoint due to the $9,000 to $13,000 cost of each missed case of CDI 170 (31). Another study found that patients diagnosed with CDI by NAAT had a two-day shorter 171 median length of stay compared to patients diagnosed by toxin immunoassay, even though 172 the patients did not differ with regard to co-morbidity, prior hospitalizations, laboratory 173 parameters or mortality (32). Length of stay is an important contributor to the financial costs 174 of CDI (33, 34), and the authors suggested that the sensitive NAAT assay might result in 175 more timely diagnosis and treatment (32). In addition, reliance on a less sensitive diagnostic 176 method may lead to more empiric therapy (35) and repeat laboratory testing, because 177 clinicians lack confidence in a negative result. Thus, the use of NAAT can promote 178 responsible antimicrobial stewardship and reduce unnecessary antibiotic and laboratory 179 utilization. 180
Polage and Wilcox-The latest guidelines recommend a two or three-step algorithm as the most 181 effective strategy to diagnose CDI and minimize over-diagnosis of C. difficile Fang-NAATs and culture-based methods are more sensitive but less specific, whereas toxin 211 assays are less sensitive but more specific. Thus, patient selection is critically important for 212 the proper interpretation of test results. With regard to specificity, it is important to 213 recognize that no C. difficile diagnostic assay is completely specific for clinical disease. 214
Production of toxin is essential but not sufficient for disease, and even patients with high 215 fecal toxin levels may be asymptomatic (37, 38), particularly if they have toxin-neutralizing 216 antibodies (39). With regard to sensitivity, it is equally important to recognize that toxin 217 assays can be negative in patients with symptomatic (and even life-threatening) CDI (10, 13, 218 40, 41). The insensitivity of toxin assays has been demonstrated even for cases of 219 pseudomembranous colitis and was a major consideration leading to the development of 220 more sensitive NAAT assays. In fact, a false-negative toxin assay is a risk factor for a fatal 221 outcome in patients with fulminant CDI (10), and I note that one of the toxin-negative 222 patients in the Polage study (2) "had recurrent CDI as a contributing factor to death." The 223 bottom line is that a negative toxin assay cannot rule-out the possibility of CDI. On the other 224 hand, the greater sensitivity of NAAT or culture-based diagnostic methods can increase the 225 likelihood of false-positive results, particularly in patients with a low clinical probability of 226 I strongly disagree with the suggestion that a negative toxin assay means that a patient is 263 only colonized and not infected (1); such a simplistic approach is likely to result in the under-264 diagnosis of CDI and harm to patients. Although some suggest that symptomatic patients 265 with CDI and negative toxin assays have self-limited disease that will resolve without 266 treatment (1, 2), this cannot be concluded from the available studies, as many of the patients 267 in these studies who had negative toxin assays received empiric treatment for CDI. 268
Furthermore, important clinical endpoints other than mortality, such as the duration and 269 severity of symptoms, were not measured, and the length-of-stay for culture-positive/toxin-270 negative patients was actually significantly longer compared to controls with both tests 271 negative (1) . Quite simply, the safety of withholding antimicrobial treatment from 272 symptomatic patients with positive NAAT and negative toxin assay results has not been 273 on also be noted that improvements in the sensitivity of toxin assays will not solve the issue of 321 false-positive results (i.e., specificity), which can be seen with any C. difficile diagnostic 322
method. 323
Polage and Wilcox-Maybe. Higher sensitivity toxin assays will decrease the number of CDI 324 cases 'missed' by toxin tests and bring the analytical and clinical performance closer to the 325 traditional cell cytotoxin neutralization assay (2, 30, 57, 58). This should be a good thing. 326
However, lowering the threshold for positive results will also decrease the specificity for CDI 327 and lead to classifying patients with transient or low levels of toxin due to C. difficile 328 colonization and antibiotic exposure as (likely erroneously) having disease (2, 57, 58). It is 329 not known whether detecting and treating these additional patients 'labelled' as having CDI 330 is necessary or beneficial (or possibly harmful) since most resolve their symptoms with 331 minimal or no treatment (2). These issues could be addressed by quantifying the level of 332 toxins to help physicians determine the likelihood that each patient has disease and warrants 333 treatment (57, 58). In any case, the overall diagnostic accuracy will depend on the test 334 performance characteristics in the population being tested. Test performance and diagnostic has concluded that reduced transmission due to the isolation of carriers was responsible for 371 the reduction in CDI incidence (65).
High-risk antibiotics (e.g., cephalosporins, 372 fluoroquinolones, clindamycin) should be avoided if at all possible in patients known to carry 373 toxigenic C. difficile, and the possibility of CDI should be immediately considered if 374 diarrhea, fever or other compatible symptoms develop. 375
Polage and Wilcox-Asymptomatic C. difficile carriers outnumber CDI patients by at least 5 to 1 376 in most hospitals and are likely to be an important source of nosocomial C. difficile 377 transmission and infection (6, 7, 62, 64). A few studies have linked asymptomatic carriers to 378 a third or more of hospital-onset CDI cases (6, 7, 61). These observations have sparked an 379 interest in screening and isolation of asymptomatic carriers as a strategy to decrease 380 healthcare-associated CDI (6, 7, 64). So far, a single before-and-after study has been 381 published with results suggesting that screening may be effective (64). However, the current 382 absence of proven interventions for asymptomatic colonization and potential ramifications of 383 isolating large numbers of patients emphasizes the need for larger, well-controlled, multi-384 center studies to confirm the effectiveness of screening before widespread adoption (7, 64). 385
Asymptomatic C. difficile colonization may also be an important predisposing risk factor 386 for CDI, but the story is somewhat mixed (59, 62, 66). Studies from the 1990s associated 387 lack of symptoms after C. difficile acquisition with pre-existing anti-toxin antibodies and 388 18 prior asymptomatic C. difficile colonization with lower risk of CDI in hospitals (59, 66). 389
These studies promoted the belief that most asymptomatic C. difficile carriers were immune 390 to C. difficile toxins but the high rate of colonization with a non-toxigenic C. difficile strain 391 (which also protects against CDI) was a potential confounder in one often mentioned review 392 (59, 66). More recently, asymptomatic C. difficile colonization has been associated with an 393 increased risk of CDI, but it is unclear if this is an artifact of NAAT testing, a change in the 394 epidemiology and pathophysiology of CDI, or simply a reflection of differential risk 395 according to the toxigenic status of colonizing strains (62). Hence, more work is needed to 396 determine the relationship between asymptomatic C. difficile carriage and subsequent risk of 397
CDI. 398
Finally, as noted above, asymptomatic C. difficile colonization is probably an important 399 source of erroneous CDI diagnoses in hospitals using C. difficile tests with poor predictive 400 value for CDI, as colonized patients with diarrheal symptoms due to medications, underlying 401 disease, and other infectious agents will yield positive (misleading) results (2, 5, 7, 67-69). 
